RU2018123197A - Композиция, содержащая ботулинический токсин - Google Patents
Композиция, содержащая ботулинический токсин Download PDFInfo
- Publication number
- RU2018123197A RU2018123197A RU2018123197A RU2018123197A RU2018123197A RU 2018123197 A RU2018123197 A RU 2018123197A RU 2018123197 A RU2018123197 A RU 2018123197A RU 2018123197 A RU2018123197 A RU 2018123197A RU 2018123197 A RU2018123197 A RU 2018123197A
- Authority
- RU
- Russia
- Prior art keywords
- botulinum neurotoxin
- composition
- paragraphs
- composition according
- units
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 16
- 108030001720 Bontoxilysin Proteins 0.000 title claims 9
- 239000003053 toxin Substances 0.000 title 1
- 231100000765 toxin Toxicity 0.000 title 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims 8
- 238000000034 method Methods 0.000 claims 4
- 230000037303 wrinkles Effects 0.000 claims 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 3
- 229920002674 hyaluronan Polymers 0.000 claims 3
- 229960003160 hyaluronic acid Drugs 0.000 claims 3
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000010118 dystonia Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000001148 spastic effect Effects 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 101710138657 Neurotoxin Proteins 0.000 claims 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 238000009499 grossing Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 239000002581 neurotoxin Substances 0.000 claims 1
- 231100000618 neurotoxin Toxicity 0.000 claims 1
- 230000010355 oscillation Effects 0.000 claims 1
- 108010074523 rimabotulinumtoxinB Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Claims (24)
1. Композиция для предотвращения или лечения дистонии, спастического состояния или морщин, содержащая
a) ботулинический нейротоксин
b) несшитую гиалуроновую кислоту, имеющую среднюю молекулярную массу от 2,5 МДа до 4,5МДа.
2. Композиция по п. 1, отличающаяся тем, что ботулинический нейротоксин представляет собой ботулинический нейротоксин типа А.
3. Композиция по п. 1 или 2, отличающаяся тем, что индекс полидисперсности несшитой гиалуроновой кислоты составляет от 1,1 до 4,0.
4. Композиция по любому из предшествующих пунктов, содержащая от 2 до 4 единиц ботулинического нейротоксина или от 20 до 40 единиц ботулинического нейротоксина на миллиграмм несшитой гиалуроновой кислоты.
5. Композиция по любому из предшествующих пунктов, отличающаяся тем, что указанная композиция дополнительно содержит
c) соль,
d) необязательно агент для стабилизации нейротоксина,
e) ингибитор кристаллизации,
f) буфер и/или
g) агент для удаления свободных радикалов.
6. Композиция по любому из предшествующих пунктов, при этом указанная композиция имеет динамическую вязкость от 1,5 до 4 Па⋅с, определенную при 25°С с применением частоты колебаний, составляющей 1 Гц.
7. Применение композиции по любому из пп. 1-6 для лечения или предотвращения дистонии, при котором вводят от 200 до 500 единиц ботулинического нейротоксина.
8. Применение композиции по любому из пп. 1-6 для лечения или предотвращения спастического состояния, при котором вводят от 500 до 1000 единиц ботулинического нейротоксина.
9. Применение композиции по любому из пп. 1-6 для предотвращения или лечения морщин, при котором вводят от 40 до 50 единиц ботулинического нейротоксина.
10. Применение по любому из пп. 7-9, отличающаяся тем, что указанная композиция остается в месте введения не более 24 часов после введения.
11. Применение по любому из пп. 7-9, отличающаяся тем, что ботулинический нейротоксин высвобождается в течение 12 часов.
12. Применение по любому из пп. 7-9, отличающаяся тем, что указанную композицию вводят каждые 4-9 месяцев.
13. Способ косметического разглаживания или предотвращения морщин у млекопитающего, при этом указанный способ включает:
(i) введение композиции по пп. 1-6, и
(и) повторение введения через 4-9 месяцев.
14. Способ по п. 13, отличающийся тем, что указанная композиция содержит от 40 до 50 единиц ботулинического нейротоксина.
15. Способ по любому из п. 13 или 14, отличающийся тем, что морщины обусловлены мимической активностью.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16158302.6 | 2016-03-02 | ||
| EP16158302 | 2016-03-02 | ||
| PCT/EP2017/054596 WO2017148915A1 (en) | 2016-03-02 | 2017-02-28 | Composition comprising botulinum toxin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018123197A true RU2018123197A (ru) | 2020-04-02 |
| RU2018123197A3 RU2018123197A3 (ru) | 2020-04-13 |
| RU2743746C2 RU2743746C2 (ru) | 2021-02-25 |
Family
ID=55527275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018123197A RU2743746C2 (ru) | 2016-03-02 | 2017-02-28 | Композиция, содержащая ботулинический токсин |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11969461B2 (ru) |
| EP (1) | EP3423084B1 (ru) |
| JP (2) | JP2019507118A (ru) |
| KR (1) | KR20180114891A (ru) |
| CN (1) | CN108463242A (ru) |
| AU (1) | AU2017227978B2 (ru) |
| BR (1) | BR112018014445A2 (ru) |
| CA (1) | CA3010146A1 (ru) |
| ES (1) | ES2893838T3 (ru) |
| MX (1) | MX2018008855A (ru) |
| RU (1) | RU2743746C2 (ru) |
| SG (1) | SG11201805195YA (ru) |
| WO (1) | WO2017148915A1 (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9161970B2 (en) * | 2007-12-12 | 2015-10-20 | Allergan, Inc. | Dermal filler |
| US11952601B2 (en) | 2017-06-20 | 2024-04-09 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum toxin with increased duration of effect |
| EP3649143B1 (en) | 2017-07-06 | 2022-08-31 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with increased duration of effect |
| CN109646673A (zh) * | 2017-10-12 | 2019-04-19 | 秀杰股份公司 | 肉毒杆菌毒素的微结构制剂技术 |
| CN108992369B (zh) * | 2018-07-02 | 2021-07-30 | 山东天晟生物科技有限公司 | 一种透明质酸、其制备方法和用途 |
| MX2021002992A (es) * | 2018-09-13 | 2021-11-12 | Allergan Inc | Composiciones de toxina clostridial y acido hialuronico. |
| WO2020069222A1 (en) * | 2018-09-26 | 2020-04-02 | Global Health Solutions Llc | Topical neurotoxin compositions |
| WO2022131860A1 (ko) * | 2020-12-18 | 2022-06-23 | 주식회사 에이티지씨 | 보툴리눔 독소의 액상 제제를 장기 보관하기 위한 약제학적 조성물 |
| WO2024126649A1 (en) | 2022-12-15 | 2024-06-20 | Merz Pharma Gmbh & Co. Kgaa | Injectable gel comprising botulinum toxin and uses thereof |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0760681B1 (en) | 1994-05-31 | 1999-09-01 | Allergan, Inc | Modification of clostridial toxins for use as transport proteins |
| WO1996039166A1 (en) | 1995-06-06 | 1996-12-12 | Wisconsin Alumni Research Foundation | Analogs of botulinum toxin and pharmaceutical compositions of botulinum toxin |
| US6214602B1 (en) | 1998-08-28 | 2001-04-10 | Promega Corporation | Host cells for expression of clostridial toxins and proteins |
| EP2267010B1 (en) | 1999-08-25 | 2014-05-07 | Allergan, Inc. | Activatable recombinant neurotoxins |
| US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
| US7491799B2 (en) | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
| US20020127247A1 (en) | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
| KR20050094817A (ko) * | 2002-12-20 | 2005-09-28 | 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. | 개선된 약제학적 보툴리늄 독소 조성물 |
| DE10333317A1 (de) | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| WO2005112970A2 (en) | 2004-05-12 | 2005-12-01 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to treat infections |
| AU2005274822B2 (en) * | 2004-07-26 | 2008-10-30 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition with a botulinum neurotoxin |
| AU2005271372B2 (en) | 2004-08-04 | 2012-05-03 | Allergan, Inc. | Optimizing expression of active botulinum toxin type A |
| DE102005002978B4 (de) | 2005-01-21 | 2013-04-25 | Merz Pharma Gmbh & Co. Kgaa | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form |
| DK2829282T3 (en) | 2007-03-22 | 2018-01-02 | Univ Colorado Regents | Process for preparing an immunologically active adjuvant-linked dried vaccine composition |
| NZ580670A (en) | 2007-06-21 | 2011-09-30 | Univ Muenchen Tech | Biological active proteins having increased in vivo and/or vitro stability |
| US9161970B2 (en) * | 2007-12-12 | 2015-10-20 | Allergan, Inc. | Dermal filler |
| US9044477B2 (en) * | 2007-12-12 | 2015-06-02 | Allergan, Inc. | Botulinum toxin formulation |
| ES2524312T3 (es) | 2008-03-14 | 2014-12-05 | Allergan, Inc. | Ensayos de actividad de serotipo A de toxina botulínica de base inmunológica |
| AU2009286973B2 (en) | 2008-08-29 | 2014-06-12 | Merz Pharma Gmbh & Co. Kgaa | Clostridial neurotoxins with altered persistency |
| EP3184552B1 (en) * | 2008-09-02 | 2020-08-12 | Tautona Group LP | Threads of hyaluronic acid, methods of making thereof and uses thereof |
| CA2749034C (en) | 2009-01-07 | 2019-01-15 | Robert John Petrella | Treatment of soft tissue injury using hyaluronic acid and botulinum toxin |
| EP2393828B1 (en) | 2009-02-03 | 2016-10-12 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
| KR101453601B1 (ko) | 2009-05-29 | 2014-10-22 | 갈데르마 리써어치 앤드 디벨로프먼트 | 주입으로 인한 피부 반응 감소를 위한 필러와 아드레날린 수용체 작용제의 주사가능한 조합 |
| RU2582266C2 (ru) | 2009-07-02 | 2016-04-20 | Мерц Фарма Гмбх Унд Ко. Кгаа | Нейротоксины, проявляющие сокращенную биологическую активность |
| WO2011109130A1 (en) * | 2010-03-01 | 2011-09-09 | Tautona Group Lp | Threads of hyaluronic acid and methods of use thereof |
| US8557961B2 (en) | 2010-04-02 | 2013-10-15 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
| WO2011123813A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| SI2571510T1 (sl) | 2010-05-21 | 2019-02-28 | Xl-Protein Gmbh | Biosintetični prolin/alaninski naključno zviti polipeptidi in njihove uporabe |
| JP2012023637A (ja) | 2010-07-15 | 2012-02-02 | Audio Technica Corp | ノイズキャンセルヘッドホン |
| FR2966348B1 (fr) | 2010-10-22 | 2012-11-09 | Galderma Res & Dev | Compositions comprenant un produit de comblement des rides et une tetracycline modifiee chimiquement |
| CA2831908C (en) * | 2011-03-31 | 2018-11-13 | Medy-Tox Inc. | Lyophilized preparation of botulinum toxin |
| RU2616281C2 (ru) | 2011-09-29 | 2017-04-13 | СЕЛЛСНЭП, ЭлЭлСи | Композиции и способы испытаний на токсикогенность |
| AU2012334076A1 (en) | 2011-11-09 | 2014-05-15 | Merz Pharma Gmbh & Co. Kgaa | Modified neurotoxins with poly-Glycine and uses thereof |
| TWI583792B (zh) | 2011-11-09 | 2017-05-21 | 曼茲法瑪股份有限公司 | 展現減短的生物活性之神經毒素 |
| BR112014012789A2 (pt) | 2011-11-28 | 2019-09-24 | Phasebio Pharmaceuticals Inc | agentes terapêuticos compreendendo sequências de aminoácidos de insulina |
| AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| GB201219602D0 (en) | 2012-10-31 | 2012-12-12 | Syntaxin Ltd | Recombinant clostridium botulinum neurotoxins |
| US20150322118A1 (en) | 2012-12-05 | 2015-11-12 | Merz Pharma Gmbh & Co. Kgaa | Recombinant clostridial neurotoxins with enhanced membrane localization |
| WO2014127258A2 (en) | 2013-02-14 | 2014-08-21 | Cornell University | Methods to protect against and treat multiple sclerosis |
| CN105339790B (zh) | 2013-06-28 | 2018-04-17 | 莫茨制药有限及两合公司 | 用于确定神经毒素多肽在细胞中的生物活性的工具和方法 |
| US9975929B2 (en) | 2014-03-05 | 2018-05-22 | Merz Pharma Gmbh & Co. Kgaa | Recombinant clostridial neurotoxins with increased duration of effect |
| JP6243577B2 (ja) | 2014-05-29 | 2017-12-06 | プロセル セラピューティックス インコーポレーティッド | 新規な細胞透過性ペプチド及びこれとボツリヌストキシン結合体、およびこれらの用途 |
| AU2015301737B2 (en) | 2014-08-12 | 2021-01-28 | Biomadison, Inc. | Botulinum neurotoxins with modified light chain specifity and methods for producing same |
| WO2016073562A1 (en) | 2014-11-04 | 2016-05-12 | Synthetic Biologics, Inc. | Methods and compositions for inhibiting clostridium difficile |
| DK3242884T3 (da) | 2015-01-09 | 2021-04-19 | Ipsen Bioinnovation Ltd | Kationiske neurotoksiner |
| WO2016180533A1 (en) | 2015-05-12 | 2016-11-17 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant clostridial neurotoxins with increased duration of effect |
| TW201718627A (zh) | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| US11078472B2 (en) | 2016-01-20 | 2021-08-03 | Merz Pharma Gmbh & Co., Kgaa | Recombinant clostridial neurotoxins with increased duration of effect |
| EP3335719A1 (en) | 2016-12-14 | 2018-06-20 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with a stabilized light chain |
| US11952601B2 (en) | 2017-06-20 | 2024-04-09 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum toxin with increased duration of effect |
| EP3649143B1 (en) | 2017-07-06 | 2022-08-31 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with increased duration of effect |
| EP3700919A1 (en) | 2017-10-26 | 2020-09-02 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with increased duration of effect |
| US20200354706A1 (en) | 2017-11-22 | 2020-11-12 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum toxin with increased duration of effect |
| CN117384259A (zh) | 2018-11-02 | 2024-01-12 | 中国医学科学院基础医学研究所 | 基于流感病毒m2蛋白的细胞穿透肽 |
-
2017
- 2017-02-28 CA CA3010146A patent/CA3010146A1/en active Pending
- 2017-02-28 AU AU2017227978A patent/AU2017227978B2/en active Active
- 2017-02-28 SG SG11201805195YA patent/SG11201805195YA/en unknown
- 2017-02-28 BR BR112018014445A patent/BR112018014445A2/pt unknown
- 2017-02-28 US US16/079,367 patent/US11969461B2/en active Active
- 2017-02-28 ES ES17707051T patent/ES2893838T3/es active Active
- 2017-02-28 EP EP17707051.3A patent/EP3423084B1/en active Active
- 2017-02-28 RU RU2018123197A patent/RU2743746C2/ru active
- 2017-02-28 WO PCT/EP2017/054596 patent/WO2017148915A1/en active Application Filing
- 2017-02-28 MX MX2018008855A patent/MX2018008855A/es unknown
- 2017-02-28 JP JP2018537506A patent/JP2019507118A/ja active Pending
- 2017-02-28 CN CN201780006844.9A patent/CN108463242A/zh active Pending
- 2017-02-28 KR KR1020187020263A patent/KR20180114891A/ko unknown
-
2022
- 2022-06-28 JP JP2022103578A patent/JP2022130574A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018014445A2 (pt) | 2018-12-11 |
| CA3010146A1 (en) | 2017-09-08 |
| MX2018008855A (es) | 2018-11-29 |
| RU2018123197A3 (ru) | 2020-04-13 |
| AU2017227978A1 (en) | 2018-07-19 |
| SG11201805195YA (en) | 2018-07-30 |
| US20190060422A1 (en) | 2019-02-28 |
| JP2019507118A (ja) | 2019-03-14 |
| US11969461B2 (en) | 2024-04-30 |
| EP3423084A1 (en) | 2019-01-09 |
| WO2017148915A1 (en) | 2017-09-08 |
| CN108463242A (zh) | 2018-08-28 |
| JP2022130574A (ja) | 2022-09-06 |
| ES2893838T3 (es) | 2022-02-10 |
| KR20180114891A (ko) | 2018-10-19 |
| RU2743746C2 (ru) | 2021-02-25 |
| AU2017227978B2 (en) | 2022-03-10 |
| EP3423084B1 (en) | 2021-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018123197A (ru) | Композиция, содержащая ботулинический токсин | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| PH12018500212A1 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
| BR112017009647A2 (pt) | 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer | |
| EA202091597A1 (ru) | Способы и композиции для лечения апноэ сна | |
| EA201270617A2 (ru) | Способы лечения или предотвращения тромбоза стента | |
| CL2021002881A1 (es) | Composiciones útiles en el tratamiento de leucodistrofia metacromática | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| MX2022002196A (es) | Composición de liberación retardada de niclosamida y uso antiviral de la misma. | |
| BR112017010238A2 (pt) | composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação de fibroblastos e a deposição aberrante de matriz extracelular | |
| BR112023023030A2 (pt) | Composições e métodos para o tratamento de depressão | |
| MX2022002597A (es) | Métodos de tratamiento de la epilepsia usando los métodos. | |
| EA202092748A1 (ru) | Модуляторы экспрессии apol1 | |
| BR112015020777A2 (pt) | Métodos para prevenir a formação de oligômeros solúveis, estruturas pré-fibrilares, protofibrilares e de fibra e placas amiloides, para redução de efeito citotóxicos de estruturas beta-enoveladas e para proteção e regeneração in vitro e/ou in vivo de células | |
| BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase | |
| MX2020001164A (es) | Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico. | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| BR112022001025A2 (pt) | Inibidores de calicreína plasmática | |
| RU2016137292A (ru) | Схема применения соединения fgf-18 | |
| BR112017014016A2 (pt) | método de redução da pressão intraocular, e, composição farmacêutica. | |
| BR112018073556A2 (pt) | medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato . | |
| PH12020551873A1 (en) | Azabenzimidazole compounds and pharmaceutical | |
| EA202192454A1 (ru) | Новый ингибитор mek для лечения вирусных и бактериальных инфекций |